Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study
2011 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 155, no 2, 244-247 p.Article in journal (Refereed) Published
This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), x3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0.03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.
Place, publisher, year, edition, pages
Blackwell Publishing , 2011. Vol. 155, no 2, 244-247 p.
acute lymphoblastic leukaemia, chemotherapy, children, consolidation, purine analogues
Engineering and Technology
IdentifiersURN: urn:nbn:se:liu:diva-72029DOI: 10.1111/j.1365-2141.2011.08835.xISI: 000296063400010OAI: oai:DiVA.org:liu-72029DiVA: diva2:455995